title: Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes.
abstract: OBJECTIVE
  Adoptive immunotherapy can be a therapeutic option to treat cancer patients with advanced-stage disease refractory to conventional therapies.
  
  
  METHODS
  We used T-cell therapy with autologous antitumor cytotoxic T lymphocytes (CTLs) in a patient with metastatic renal cell carcinoma. Autologous antitumor CTLs obtained by stimulating CD8-enriched cells with dendritic cells pulsed with irradiated apoptotic tumor cells and expanded in vitro were transfused on days +14 and +28 following chemotherapy and every 2 to 4 months thereafter.
  
  
  CONCLUSIONS
  Treatment with high doses of antitumor CTLs proved to be safe and induced immunological responses and long-lasting clinical benefit in our patient.
authors: Simona
authors: S
authors: Secondino
authors: Ilaria
authors: I
authors: Turin
authors: Enrica
authors: E
authors: Montini
authors: Camillo
authors: C
authors: Porta
authors: Rita
authors: R
authors: Maccario
authors: Paolo
authors: P
authors: Pedrazzoli
authors: Daniela
authors: D
authors: Montagna
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D018450:Disease Progression; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation*; D013997:Time Factors; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome